Archive
Imatinib in gastrointestinal stromal tumors (GIST): Northern Cancer Network Experience
F. Azribi, r. r. r. Razak, p. Dildey, j. Adam, j. Wilsdon and m. Verrill
Treatment of imatinib in unusable or metastatic gastrointestinal stromal tumors (GIST) has shifted the paradigm of treatment of this disease. Successful clinical trials of imatinib brought rapid regulatory approval and, in England and Wales, National Institute for Health and Clinical Excellence orientation (NICE) on the use of this technology.NICE detailed review of their recommended guidelines in clinical practice. Audit reflects that orientation and is designed to document the use of imatinib in routine clinical practice.
Methods: we conducted a retrospective audits of GIST patients treated with imatinib since 1 February 2002 to 31 March 2007. Information collected included patient demographics, the characteristics of the disease and details of the treatment administered, treatment response, toxicity and follow-up data.The primary goal was to record the disease control rate (DCR), defined as a lack of progress on computed tomography (CT) to 3 months. secondary end Points of the audits were devoid of overall survival and progression. These were compared with the results of published trials.
Results: were identified six thirty consecutive patients with diagnosed GIST treated with imatinib. The median age of patients was 70.1 years. During the analysis, patients were followed for a median of 41.6 months. In total, patients were treated to a median of 15,8 months.Treatment is generally well tolerated with a small percentage of patients experiencing the toxicity of grade 3/4. Control of the disease has been reported in 30 patients (DCR, 83.3%, 95% CI 67.2-93.6, intention to treat analysis).The median progression-free survival (PFS) in this cohort was 16.4 months (95% CI: 12.9-34,4);While the median overall survival (OS) was 39.7 months (95% CI: 22.8-56.5).
Conclusion: the data showed that treatment of patients with gist selected within the Guide NICE compares favorably to data previously published randomized studies of imatinib. registration of the note, the average age of this cohort is about 10 years earlier than the one reported in the trials. Imatinib was well tolerated with treatment related adverse events are acceptable.
Volume: 3 article number: 162 DOI: 10.3332/ecancer. 2010.162 received: 10/10/2009 published: 14/12/2009
To view this article in its entirety, you must first sign in or register.
Institutional guidelines and ongoing studies in the management of liver tumors: the experience of the European Institute of Oncology
Zampino by m.g. Biffi, f. bears, r. r. Chiappa, n. Funk, f. De Braud, Bonomo g., l. Monfardini, p. Della Vigna, f. Luke, l. Bodei, m. Bartolomei, g. Catalano, M.C. Leonardi, m. Ferrari, b. Andreoni, r. g. Goldhirsch, Paganelli, r. Orecchia
Background:
A task force on upper gastrointestinal cancers institutional is active at the European Institute of Oncology (IEO). Members decided to gather in a document of institutional guidelines on managing liver tumors (primary and metastatic). This article is intended to present the current treatment guidelines and protocols of ongoing research and experiments in this field at IEO.
Methods:
A Steering Committee is convened to assign tasks to individual members. expert Contributions in every area of treatment were collected in a single document in order to produce a draft for later review by the aforementioned Committee. Six drafts discussed and approved the final version.
Results:
Surgical, medical oncology approaches, Interventional Radiology, nuclear medicine and radiotherapy, their roles in the management of hepatic tumors and ongoing research trials are presented and discussed in this article.
Conclusions:
At the European Institute of Oncology, a multidisciplinary and integrated approach for liver tumors is a standard and many ongoing research projects are currently active in this field.
Volume: 2 article number: 64 DOI: 10.3332/eCMS. 2008.64 received: 28/12/2007 published: 02/05/2008
To view this article in its entirety, you must first sign in or register.
Report of the second International Symposium on molecular epidemiology in childhood leukemias and embryonic tumors, Rio de Janeiro, Brazil
M.S. Pombo de Oliveira, s. Ferman, b. de Camargo
Recent molecular-International Symposium on epidemiology in embryonal tumors and pediatric leukemia was held on 4-6 March 2008 in Rio de Janeiro, Brazil. Was a very productive meeting in which studies relating to genetics and therapeutic trials, identification of risk factors for neuroblastoma in acute leukemia and cancer Wilms were presented. Over 120 participants gathered for three days of fruitful discussions, including representatives of Pediatrics, hematology, pathology, laboratory and epidemiology.Discussions on strategies for biomarker applications relevant to clinical studies were discussed. Highlights of each scientific presentations are summarised below.
Volume: 2 article number: 86 DOI: 10.3332/eCMS. 2008.86 received: 30/05/2008 published: 05/06/2008
To view this article in its entirety, you must first sign in or register.
cancer3 